Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability

Qi Xue, Benjamin Hopkins, Carole Perruzzi, Durga Udayakumar, David Sherris, Laura E. Benjamin

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

It has become clear that the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is central for promoting both tumor and tumor stroma and is therefore a major target for anticancer drug development. First- and second-generation rapalogs (prototypical mTOR inhibitors) have shown promise but, due to the complex nature of mTOR signaling, can result in counterproductive feedback signaling to potentiate upstream Akt signaling. We present a novel PI3K/Akt/mTOR inhibitor, Palomid 529 (P529), which inhibits the TORC1 and TORC2 complexes and shows both inhibition of Akt signaling and mTOR signaling similarly in tumor and vasculature. We showtha t P529 inhibits tumor growth, angiogenesis, and vascular permeability. It retains the beneficial aspects of tumor vascular normalization that rapamycin boasts. However, P529 has the additional benefit of blocking pAktS473 signaling consistent with blocking TORC2 in all cells and thus bypassing feedback loops that lead to increased Akt signaling in some tumor cells.

Original languageEnglish (US)
Pages (from-to)9551-9557
Number of pages7
JournalCancer Research
Volume68
Issue number22
DOIs
StatePublished - Nov 15 2008

Fingerprint

Capillary Permeability
Sirolimus
Growth
Phosphatidylinositol 3-Kinase
Pharmaceutical Preparations
Neoplasms
Blood Vessels
mechanistic target of rapamycin complex 1
TOR complex 2
palomid 529

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. / Xue, Qi; Hopkins, Benjamin; Perruzzi, Carole; Udayakumar, Durga; Sherris, David; Benjamin, Laura E.

In: Cancer Research, Vol. 68, No. 22, 15.11.2008, p. 9551-9557.

Research output: Contribution to journalArticle

Xue, Qi ; Hopkins, Benjamin ; Perruzzi, Carole ; Udayakumar, Durga ; Sherris, David ; Benjamin, Laura E. / Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. In: Cancer Research. 2008 ; Vol. 68, No. 22. pp. 9551-9557.
@article{67b675acc3fb4ada942181efdc3e4f7a,
title = "Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability",
abstract = "It has become clear that the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is central for promoting both tumor and tumor stroma and is therefore a major target for anticancer drug development. First- and second-generation rapalogs (prototypical mTOR inhibitors) have shown promise but, due to the complex nature of mTOR signaling, can result in counterproductive feedback signaling to potentiate upstream Akt signaling. We present a novel PI3K/Akt/mTOR inhibitor, Palomid 529 (P529), which inhibits the TORC1 and TORC2 complexes and shows both inhibition of Akt signaling and mTOR signaling similarly in tumor and vasculature. We showtha t P529 inhibits tumor growth, angiogenesis, and vascular permeability. It retains the beneficial aspects of tumor vascular normalization that rapamycin boasts. However, P529 has the additional benefit of blocking pAktS473 signaling consistent with blocking TORC2 in all cells and thus bypassing feedback loops that lead to increased Akt signaling in some tumor cells.",
author = "Qi Xue and Benjamin Hopkins and Carole Perruzzi and Durga Udayakumar and David Sherris and Benjamin, {Laura E.}",
year = "2008",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-08-2058",
language = "English (US)",
volume = "68",
pages = "9551--9557",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability

AU - Xue, Qi

AU - Hopkins, Benjamin

AU - Perruzzi, Carole

AU - Udayakumar, Durga

AU - Sherris, David

AU - Benjamin, Laura E.

PY - 2008/11/15

Y1 - 2008/11/15

N2 - It has become clear that the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is central for promoting both tumor and tumor stroma and is therefore a major target for anticancer drug development. First- and second-generation rapalogs (prototypical mTOR inhibitors) have shown promise but, due to the complex nature of mTOR signaling, can result in counterproductive feedback signaling to potentiate upstream Akt signaling. We present a novel PI3K/Akt/mTOR inhibitor, Palomid 529 (P529), which inhibits the TORC1 and TORC2 complexes and shows both inhibition of Akt signaling and mTOR signaling similarly in tumor and vasculature. We showtha t P529 inhibits tumor growth, angiogenesis, and vascular permeability. It retains the beneficial aspects of tumor vascular normalization that rapamycin boasts. However, P529 has the additional benefit of blocking pAktS473 signaling consistent with blocking TORC2 in all cells and thus bypassing feedback loops that lead to increased Akt signaling in some tumor cells.

AB - It has become clear that the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is central for promoting both tumor and tumor stroma and is therefore a major target for anticancer drug development. First- and second-generation rapalogs (prototypical mTOR inhibitors) have shown promise but, due to the complex nature of mTOR signaling, can result in counterproductive feedback signaling to potentiate upstream Akt signaling. We present a novel PI3K/Akt/mTOR inhibitor, Palomid 529 (P529), which inhibits the TORC1 and TORC2 complexes and shows both inhibition of Akt signaling and mTOR signaling similarly in tumor and vasculature. We showtha t P529 inhibits tumor growth, angiogenesis, and vascular permeability. It retains the beneficial aspects of tumor vascular normalization that rapamycin boasts. However, P529 has the additional benefit of blocking pAktS473 signaling consistent with blocking TORC2 in all cells and thus bypassing feedback loops that lead to increased Akt signaling in some tumor cells.

UR - http://www.scopus.com/inward/record.url?scp=56449087509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56449087509&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-2058

DO - 10.1158/0008-5472.CAN-08-2058

M3 - Article

C2 - 19010932

AN - SCOPUS:56449087509

VL - 68

SP - 9551

EP - 9557

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 22

ER -